Connection

Francis Spinale to Matrix Metalloproteinases

Back to Details
This is a "connection" page, showing publications Francis Spinale has written about Matrix Metalloproteinases.
Francis Spinale
Connection Strength
9.940
Matrix Metalloproteinases
  1. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 01; 90(1):7-15.
    View in: PubMed
    Score: 0.411
  2. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
    View in: PubMed
    Score: 0.375
  3. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
    View in: PubMed
    Score: 0.360
  4. Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation. 2011 Sep 13; 124(11 Suppl):S35-45.
    View in: PubMed
    Score: 0.343
  5. Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy. Eur J Heart Fail. 2011 Mar; 13(3):271-7.
    View in: PubMed
    Score: 0.325
  6. Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy. Cardiol Young. 2011 Feb; 21(1):52-61.
    View in: PubMed
    Score: 0.323
  7. Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation. 2010 Jul 06; 122(1):20-32.
    View in: PubMed
    Score: 0.315
  8. Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants. J Thorac Cardiovasc Surg. 2010 Dec; 140(6):1257-65.
    View in: PubMed
    Score: 0.315
  9. Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. Ann Thorac Surg. 2010 Jun; 89(6):1843-52; discussion 1852.
    View in: PubMed
    Score: 0.314
  10. Short-term disruption in regional left ventricular electrical conduction patterns increases interstitial matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H217-24.
    View in: PubMed
    Score: 0.313
  11. Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation. 2008 Sep 30; 118(14 Suppl):S16-23.
    View in: PubMed
    Score: 0.279
  12. Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass. J Cardiovasc Pharmacol. 2008 Apr; 51(4):418-23.
    View in: PubMed
    Score: 0.270
  13. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 Oct; 87(4):1285-342.
    View in: PubMed
    Score: 0.261
  14. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006 Sep 05; 114(10):1020-7.
    View in: PubMed
    Score: 0.241
  15. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol. 2006 Feb; 47(2):228-35.
    View in: PubMed
    Score: 0.232
  16. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006 Feb 15; 69(3):666-76.
    View in: PubMed
    Score: 0.232
  17. Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. Circ Res. 2005 May 27; 96(10):1110-8.
    View in: PubMed
    Score: 0.220
  18. Disruptions and detours in the myocardial matrix highway and heart failure. Curr Heart Fail Rep. 2005 Mar; 2(1):10-7.
    View in: PubMed
    Score: 0.218
  19. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005 May 01; 66(2):410-9.
    View in: PubMed
    Score: 0.215
  20. The effects of leukocyte reduction on matrix metalloproteinase release in cardiopulmonary bypass. J Extra Corpor Technol. 2004 Jun; 36(2):185-90.
    View in: PubMed
    Score: 0.207
  21. Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur Heart J. 2004 Apr; 25(8):631-3.
    View in: PubMed
    Score: 0.205
  22. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003 Jun 10; 107(22):2857-63.
    View in: PubMed
    Score: 0.193
  23. Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol. 2003 May; 35(5):539-48.
    View in: PubMed
    Score: 0.192
  24. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003 Mar; 125(3):602-10.
    View in: PubMed
    Score: 0.190
  25. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2002 Dec 18; 40(12):2165-73.
    View in: PubMed
    Score: 0.187
  26. Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. Circ Res. 2002 Dec 13; 91(12):1082-4.
    View in: PubMed
    Score: 0.187
  27. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
    View in: PubMed
    Score: 0.186
  28. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1288-95.
    View in: PubMed
    Score: 0.178
  29. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
    View in: PubMed
    Score: 0.178
  30. Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction. Heart Rhythm. 2022 05; 19(5):847-855.
    View in: PubMed
    Score: 0.176
  31. Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. Int Heart J. 2021 Sep 30; 62(5):1096-1105.
    View in: PubMed
    Score: 0.172
  32. Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling. J Pharmacol Exp Ther. 2020 11; 375(2):296-307.
    View in: PubMed
    Score: 0.160
  33. Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling. Circ Cardiovasc Imaging. 2019 11; 12(11):e009055.
    View in: PubMed
    Score: 0.151
  34. Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness. Exp Gerontol. 2019 08; 123:36-44.
    View in: PubMed
    Score: 0.146
  35. Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
    View in: PubMed
    Score: 0.097
  36. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol. 2013 Mar 01; 304(5):C393-402.
    View in: PubMed
    Score: 0.093
  37. Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012 Feb; 93(2):457-63.
    View in: PubMed
    Score: 0.087
  38. Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg. 2012 Jan; 143(1):215-23.
    View in: PubMed
    Score: 0.087
  39. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging. 2011 Jul; 4(4):381-91.
    View in: PubMed
    Score: 0.083
  40. Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms. J Cardiovasc Pharmacol. 2010 Apr; 55(4):408-16.
    View in: PubMed
    Score: 0.078
  41. Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg. 2010 Apr; 139(4):984-90; discussion 990.
    View in: PubMed
    Score: 0.078
  42. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation. 2009 Sep 15; 120(11 Suppl):S220-9.
    View in: PubMed
    Score: 0.075
  43. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail. 2008 Feb; 10(2):125-8.
    View in: PubMed
    Score: 0.067
  44. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.065
  45. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007 Apr; 133(4):1028-36.
    View in: PubMed
    Score: 0.063
  46. Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation. J Thorac Cardiovasc Surg. 2006 Oct; 132(4):788-95.
    View in: PubMed
    Score: 0.061
  47. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 2006 Jul 04; 114(1 Suppl):I365-70.
    View in: PubMed
    Score: 0.060
  48. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
    View in: PubMed
    Score: 0.059
  49. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
    View in: PubMed
    Score: 0.058
  50. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005 Nov 15; 112(20):3157-67.
    View in: PubMed
    Score: 0.057
  51. Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol. 2005 May; 20(3):211-6.
    View in: PubMed
    Score: 0.055
  52. Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation. 2004 Sep 14; 110(11 Suppl 1):II268-73.
    View in: PubMed
    Score: 0.053
  53. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003 Feb 07; 92(2):177-85.
    View in: PubMed
    Score: 0.047
  54. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
    View in: PubMed
    Score: 0.047
  55. Extracellular matrix remodeling following myocardial injury. Ann Med. 2003; 35(5):316-26.
    View in: PubMed
    Score: 0.047
  56. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002 Dec; 8(6 Suppl):S332-8.
    View in: PubMed
    Score: 0.047
  57. Matrix Metalloproteinase-Targeted SPECT/CT Imaging for Evaluation of Therapeutic Hydrogels for the Early Modulation of Post-Infarct Myocardial Remodeling. J Cardiovasc Transl Res. 2023 Feb; 16(1):155-165.
    View in: PubMed
    Score: 0.045
  58. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002 Mar; 53(4):822-30.
    View in: PubMed
    Score: 0.044
  59. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arterioscler Thromb Vasc Biol. 2016 Apr; 36(4):636-46.
    View in: PubMed
    Score: 0.029
  60. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014 Jun; 13(6):653-61.
    View in: PubMed
    Score: 0.026
  61. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol. 2008 Jan 29; 51(4):476-86.
    View in: PubMed
    Score: 0.017
  62. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther. 2006 Sep; 318(3):966-73.
    View in: PubMed
    Score: 0.015
  63. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004 Jan 20; 109(2):262-8.
    View in: PubMed
    Score: 0.013
  64. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol. 2003 Jan; 284(1):H122-32.
    View in: PubMed
    Score: 0.012
  65. Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol. 2002 Jun; 282(6):H2324-35.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.